Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Sarcoma 1Gynecologic 1

Conditions

Melanoma 2Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × elesclomol × Dermatologic × Clear all
NCT00084214 2014-03-06

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Synta Pharmaceuticals Corp.

Phase 1/2 Completed
103 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00522834 2014-03-04

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Synta Pharmaceuticals Corp.

Phase 3 Terminated
630 enrolled
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡